Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 31, 2024Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMatthew LeiMassachusetts General HospitalMSMark N SorialMassachusetts General HospitalULUvette LouMassachusetts General Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lei et al. (2024) studied this question.

synapsesocial.com/papers/6a9587e37cf22ac2aff224e8https://doi.org/10.1080/10428194.2024.2310144
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice2020 · 23 citations
  2. 2Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings2020 · 5 citations
  3. 3VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY2023 · 13 citations
  4. 4A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies2016 · 188 citations
  5. 5Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia2018 · 940 citations